
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K/A
Amendment No. 1

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 10, 2014

AMERICAN LIBERTY PETROLEUM CORP.

(Exact name of Registrant as specified in charter)

Nevada (State of Other Jurisdiction of Incorporation)	000-54004 (Commission File Number)	98-0599151 (IRS Employer Identification No.)
--------------------------------------------------------------------	-------------------------------------------------	-----------------------------------------------------------

11251 Richmond Avenue, Suite F101 Houston, Texas (Address of Principal Executive Offices)	77082 (Zip Code)
---------------------------------------------------------------------------------------------------------------	----------------------------

(281) 600 - 6000
Registrant's telephone number, including area code

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- £ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - £ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - £ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - £ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

Explanatory Note

This Amendment No. 1 to the 8-K is being filed to disclose the exemption from registration that was relied upon when issuing the equity securities without registration.

Item 1.01 Entry into a Material Definitive Agreement.

September 1, 2014 we signed a letter of intent to acquire Avant Diagnostics Inc., a Nevada corporation with headquarters at 8561 East Anderson Drive, Suite 104, Scottsdale, AZ 85255. The letter of intent was approved by our board of directors prior to signing but was not approved by Avant's board of directors until September 10, 2014. Avant Diagnostics Inc. is a medical technology company developing cutting edge medical tests, including OvaDx®, a Pre-Symptomatic Ovarian Cancer Screening Test.

Effective October 1, 2014, we modified the closing date specified in the letter of intent and amended the provisions with respect to due diligence by the parties.

Item 3.02 Unregistered Sales of Equity Securities.

Effective October 1, 2014 we issued a total of three million Common Stock shares, ratably, to three major shareholders in exchange for 68,469,993 outstanding Common Stock shares that were cancelled and returned to the status of authorized and unissued shares. The shares were issued without registration under the Securities Act of 1933 in reliance on the exemption from registration under Section 3(a)9 of the Securities Act as a transaction involving the exchange of securities of the same issuer as well as Section 4(a)2 and Rule 506(b) as an offering and sale without public solicitation.

Item 9.01 Financial Statements and Exhibits

- 99.01 Press release for share exchange
- 99.02 Amendment #1 to Letter of Intent

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

AMERICAN LIBERTY PETROLEUM CORP.
(Registrant)

Signature

Title

Date

/s/ Robert C. Rhodes
Robert C. Rhodes

Chief Executive Officer

October 3, 2014

EXHIBIT 99.01

American Liberty Petroleum Corp. cancels majority of its stock

Houston, Texas (Wednesday, October 1, 2014) – American Liberty Petroleum Corp. announces today that it will cancel over sixty three percent (63%) of the company's outstanding Common Stock shares. Three major shareholders have signed an agreement to exchange stock certificates, owned by them and already submitted to the company's CFO, for one million (1,000,000) Common Stock shares each – for a total of over sixty eight million (68,469,993) Common Stock shares being cancelled and three million (3,000,000) being issued.

“ These shareholders, including the Chief Executive Officer prior to Mr. Rhodes, believe that our current management team and its plan focusing on enhancing shareholder value will bring major benefits to our shareholders, ” said Steven M. Plumb, American Liberty Petroleum Corp.'s Chief Financial Officer. *“ With 107,389,051 Common Stock shares outstanding as of the filing of our last 10Q, we are cancelling over sixty three percent (63%) of the outstanding Common Stock shares. ”*

The previously disclosed letter of intent for acquisition of Avant Diagnostics Inc. contemplates a closing date by October 1st, 2014, based upon successful conclusion of due diligence, which is ongoing by both parties. The parties have signed an amended letter of intent providing for a later closing, October 31, after Avant Diagnostics Inc. submits a PCAOB audit to the company as part of the due diligence.

Shareholders should also note that Mr. Hunter M.A. Carr no longer has any position nor ownership in American Liberty Petroleum Corp. The Board of Directors accepted Mr. Carr's resignation as Chairman on August 30, 2014.

About American Liberty Petroleum Corp.

American Liberty Petroleum Corp. ('OREO', <http://americanlibertypetroleum.com/>) is a fully reporting, development stage publicly traded company seeking acquisitions in the Gulf Coast oil & gas services business segment. OREO's current management team, Robert C. Rhodes (CEO) and Steven M. Plumb (CFO), are actively involved in the search for acquisitions.

About Avant Diagnostics Inc.

Avant Diagnostics, Inc. ('Avant', <http://avantdiagnostics.com>) is a medical technology company based on the completion of the human genome sequencing project. Avant is developing specialized tests that are cutting edge in medical diagnostic testing and the OvaDx® Pre-Symptomatic Ovarian Cancer Screening Test is a leading breakthrough in commercializing these tests.

Genetic research is increasingly focused on identifying the variations of the specific genes in the genome. These variations are what define individual characteristics, including disease states or a statistical propensity for disease. The implications are far-reaching and impact not only the research community, but also the individual patients and the medical providers. Diagnostic tests that detect diseases very early in their progression will provide options for earlier treatments that may improve the patient's quality of life and prognosis by delaying or preventing disease progression or even death. Medical providers will incur major cost savings by avoiding costly late stage disease treatments.

Safe Harbor

The statements in this press release that relate to American Liberty Petroleum Corp.'s expectations with regard to the future impact on American Liberty Petroleum Corp.'s results from new products and services in development, including any planned acquisitions, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The results anticipated by any or all of these forward-looking statements might not occur. American Liberty Petroleum Corp. undertakes no obligation to publicly release the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof, or to reflect the occurrence of unanticipated events or changes in American Liberty Petroleum Corp.'s plans or expectations.

Investor Contact

Robert C. Rhodes
American Liberty Petroleum Corp.
investors@americanlibertypetroleum.com

Steven Scott or Gregg Linn
Avant Diagnostics, Inc.
investors@avantdiagnostics.com



American Liberty Petroleum Corp.
11251 Richmond Avenue, Suite F101, Houston, Texas 77082
<http://americanlibertypetroleum.com> - 281- 600 -6000

Wednesday, October 1st, 2014

Steven Scott
CEO
Avant Diagnostics Inc.
8561 East Anderson Drive, Suite 104
Scottsdale, AZ 85255

RE: Amended #1 to the Letter of Intent to purchase Avant Diagnostics Inc. by American Liberty Petroleum Corp.

Mr. Scott,

This documents amends the Letter of Intent signed between American Liberty Petroleum Corp., a publicly traded Nevada corporation in good standing, with headquarters at 11251 Richmond Avenue, Suite F101, Houston, Texas 77082 ("**BUYER**"), and Avant Diagnostics Inc., a Nevada corporation in good standing with headquarters at 8561 East Anderson Drive, Suite 104, Scottsdale, AZ 85255 ("**ACQUISITION**"). The amendment is as follows:

- Paragraph (l)(a) is amended as follows:

"A closing date of no later than October 31st, 2014 or thirty one (31) days following the signing of this amendment to the LOI, whichever is later ("CLOSING DATE"), but will be effective as of October 1st, 2014 ("EFFECTIVE DATE")."

- Paragraph (l)(b) is amended as follows:

"Closing of the ACQUISITION is predicated upon the results of due diligence of ACQUISITION to BUYER's satisfaction, which will be completed no later than the CLOSING DATE. SELLER will engage of PCAOB auditor and provide a PCAOB audit to BUYER as part of due diligence."

AGREED:

/s/ Robert C. Rhodes

October 1st, 2014

Robert C. Rhodes
CEO, President of American Liberty Petroleum Corp.

Date

Steven Scott
President of Avant Diagnostics Inc.

Date

